Cellectis S.A. (NASDAQ: CLLS) Stock Information | RedChip

Cellectis S.A. (NASDAQ: CLLS)


$1.6100
-0.0300 ( +1.26% ) 0.6K

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

Market Data


Open


$1.6100

Previous close


$1.6400

Volume


0.6K

Market cap


$164.15M

Day range


$1.6100 - $1.6450

52 week range


$1.5300 - $3.5500

SEC Filings


Form Type Description Pages Date
6-k Form 6-K 2 May 28, 2024
6-k Form 6-K 2 May 24, 2024
6-k Form 6-K 2 May 06, 2024
6-k Form 6-K 3 May 03, 2024
20-f Annual reports 149 Apr 29, 2024
6-k Form 6-K 2 Apr 22, 2024
6-k Form 6-K 2 Apr 10, 2024
6-k Form 6-K 2 Apr 08, 2024
6-k Form 6-K 2 Jan 16, 2024
6-k Form 6-K 2 Dec 22, 2023

Latest News